insider24.ch
Back to the feed

Shareholding disclosure

HBM BioVentures Cayman Ltd

inBasilea Pharmaceutica AG, Allschwil

Declared position

5.6%

Threshold

Crossed upwards

Timeline

Published

02.04.2008

Transaction

20.03.2008

Transfer date

20.03.2008

Voting rights breakdown

Voting rights acquired5.6%
Voting rights sold0%
Below threshold0%

Notice details

CategoryGroup of shareholders
ExchangeXSWX

Notification ID

T5992D5749

Beneficial owner

HBM BioVentures Cayman Ltd

Declared address

HBM BioVentures (Cayman) Ltd., Grand Cayman

HBM BioVentures (Cayman) Ltd., Centennial Tower, 3rd Floor, 2454 West Bay Road, Grand Cayman, Cayman Islands, eine hundertprozentige Tochtergesellschaft von HBM BioVentures AG, Grabenstrasse 25, 6340 Baar, Schweiz, meldet am 25. März 2008 an die Basilea Pharmaceutica AG den Verfall der Call-Optionen BSLDU/ISIN; 0028814678 sowie die Ausübung der OTC-Put-Optionen DB BSLN durch den Vertragspartner. HBM BioVentures Ltd. hält neu an der Basilea Pharmaceutica AG Erwerbspositionen gemäss Art. 10 Abs. 3 lit. a BEHV-EBK, bestehend aus 534 000 Namenaktien, entsprechend einem Stimmrechtsanteil von 5,60%.

Open shareholder profileOpen company profile

These figures aggregate public disclosures. They are not investment advice.

Source: SIX Exchange Regulation

insider24.ch

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication
Unlimited company trackingUnlimited watchlist with the Pro plan
Monday recapYour stocks' essentials at the open